86
Participants
Start Date
August 17, 2023
Primary Completion Date
July 31, 2025
Study Completion Date
November 30, 2025
Naporafenib
Naporafenib (ERAS-254) 200 mg twice daily (BID) of an experimental Pan-Raf inhibitor
Trametinib
Trametinib is an FDA approved anticancer medication that targets MEK1 and MEK2.
Inova Schar Cancer Institute, Fairfax
NEXT Virginia, Fairfax
Emory University School of Medicine, Atlanta
Florida Cancer Specialists - St. Petersburg, St. Petersburg
Florida Cancer Specialists - Sarasota, Sarasota
SCRI Oncology Partners (formerly Tennessee Oncology), Nashville
Inje University Haeundae Paik Hospital, Busan
Henry Ford Health System, Detroit
University of Wisconsin, Madison
Washington University School of Medicine, St Louis
The University of Texas MD Anderson Cancer Center, Houston
Comprehensive Cancer Center of Nevada (CCCN), Las Vegas
University of California, San Francisco, San Francisco
Oregon Health & Science University, Portland
Yale Cancer Center, New Haven
Macquarie University, Macquarie Park
St. Vincent's Hospital, Melbourne
Linear Clinical Research, LTD, Perth
London Regional Cancer Center, London
National Cancer Center, Goyang-si
Seoul National University Hospital Bundang, Gyeonggi-do
Seoul National University Hospital, Seoul
The Catholic University Hospital, Seoul
Beatson West of Scotland Cancer Center, Glasgow
Cross Cancer Institute- Alberta Health Services (AHS), Edmonton
British Columbia Cancer Agency, Vancouver
Princess Margaret Cancer Centre, Toronto
Samsung Medical Center, Seoul
Sarah Cannon Research Institute - HCA Healthcare, City of London
Erasca, Inc.
INDUSTRY